Skip to content
OpenCapital
Get started

Novavax NVAX Enterprise value

Enterprise value at other companies

Moderna logo
ModernaMRNA
$19.57B+93.6%
Roivant Sciences logo
Roivant SciencesROIV
$18.51B+157%
Merck & Co. logo
Merck & Co.MRK
$341.11B+34.2%
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
$8.22B+78.6%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.86B+85.0%
ALN
Alnylam PharmaceuticalsALNY
$42.43B+24.1%

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+28.6%
P/S2.5×+1.5×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%—
Debt / equity1.5×—
Current ratio2.5×+0.4×

Where this comes from

Calculated from Novavax’s reported figures.

$1.3Bmarket cap+$295.1Mtotal debt−$228.4Mcash and equivalents=$1.39B

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's enterprise value?
Novavax (NVAX) reported enterprise value of $1.39B in Q1 2026.
How has Novavax's enterprise value changed year-over-year?
Novavax's enterprise value increased by 68.6% year-over-year, from $826.21M to $1.39B.
What is the long-term trend for Novavax's enterprise value?
Over 5 years (2020 to 2025), Novavax's enterprise value has grown at a -32.7% compound annual growth rate (CAGR), from $8.18B to $1.13B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.